Given the variability in biomarker cut‐offs and the potential for misclassification, particularly in AAs, our findings underscore the need to account for comorbidities such as BBB dysfunction, which may influence CSF tau levels and impact both AD diagnostics and the assessment of tau‐targeting therapies in clinical trials. Here, MAPT is linked to Alzheimer disease.